Sunflower Pharmaceutical recently stated in a conference call with institutional investors that in terms of gross margin, from the beginning of the fourth quarter of last year to the first quarter of this year, the increase in prices of raw materials for Chinese herbal medicines has put some upward pressure on raw material costs. Looking at it now, after the price of Chinese herbal medicines has reached a high level, with the exception of individual varieties, it is generally in a steady state of decline, and the upward pressure on costs may ease in the future. In the past year, the company's gold single product strategy was effectively implemented. The annual shipment amount of liver protection tablets exceeded 1 billion yuan for the first time, making it the first 1 billion single product in the company's history. The basic market for children's respiratory products was stable, and the product matrix continued to stabilize. In the future, the company will further focus on the three major fields of children's medicine, chronic diseases, and gynecological medicine to expand the size of the gold single product group.